Will breast cancer not relapse with TDM1 Ado-trastuzumab emtansine?

Ado-trastuzumab emtansine is an antibody-drug conjugate that combines trastuzumab and the cytotoxic agent emtansine. In the KATHERINE trial, trastuzumab reduced disease recurrence compared with trastuzumab in patients with invasive disease after neoadjuvant HER2-targeted therapy for breast cancer. Trastuzumab was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of patients who develop invasive disease after neoadjuvant trastuzumab treatment.

The risk of breast cancer recurrence varies based on many factors, including the grade and stage of the tumor, the patient's personal characteristics and genetic mutations. Although trastuzumab can significantly prolong progression-free survival and overall survival in many cases, tumor recurrence is still possible. To minimize the risk of recurrence, doctors often develop a comprehensive treatment plan based on the patient's specific situation. This may involve surgical removal, radiation therapy, chemotherapy or other medical treatments. In addition, regular follow-up and monitoring are important so that any signs of recurrence can be detected and managed early.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.